Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment

Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment

Abstract Background The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. Case presentation We describe an autoimmune polymyositis following a partial response to combination tremelimumab and durvalumab f...

Full description

Bibliographic Details
Main Authors: Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner, Ben C. Creelan
Format: Article
Language:English
Published: BMJ Publishing Group 2017-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune-related adverse event
Non-small cell lung cancer
Programmed death protein 1
Programmed death-ligand 1
Cytotoxic T-lymphocyte-associated-protein 4
Immune checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-017-0258-x

Internet

http://link.springer.com/article/10.1186/s40425-017-0258-x

Similar Items